Annals of Stomatology 2024 May-August; 2(2): 83-86
LETTER TO THE EDITOR
MEDICATION-RELATED OSTEONECROSIS OF JAW
K. Chatterjee1, A. Banerjee1*, S. Khan2, R. Franco3, H. Uzunçıbuk4, G. Cervino5 and G. Minervini6,7
1Department of Oral and Maxillofacial Pathology, Awadh Dental College and Hospital, Jamshedpur;
2Department of Oral Pathology, KGF College Of Dental Sciences And Hospital, Karnataka, India;
3Department of Biomedicine and Prevention, the University of Rome “Tor Vergata”, Rome, Italy;
4Department of Orthodontics, Faculty of Dentistry, Trakya University, Edirne, Turkey;
5Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico “Gaetano Martino”, Messina, Italy;
6Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India;
7Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania Luigi Vanvitelli, Naples, Italy
Correspondence to:
Abhishek Banerjee, MD
Department of Oral and maxillofacial pathology,
Awadh Dental College and Hospital,
NH-33, Danga, P.O. Bhilaipahar, Jamshedpur,
Jharkhand 831012, India
e-mail: abhishek.banerjee376@gmail.com
Received: 13 April 2024 Accepted: 16 May 2024 |
ISSN 2975-1276 [online] Copyright 2024 © by BIOLIFE This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder. Unauthorized reproduction may result in financial and other penalties. Disclosure: all authors report no conflicts of interest relevant to this article. |
KEYWORDS: bisphosphonates, medication-related osteonecrosis of jaw, antiresorptive, denosumab
